论文部分内容阅读
目的:检测PDCD4和DNMT1在正常卵巢组织、卵巢良性肿瘤组织、卵巢上皮性癌组织中的表达,并探讨其临床意义。方法:采用免疫组化法检测20例正常卵巢、25例卵巢良性肿瘤、40例卵巢上皮性癌组织中PDCD4和DNMT1的表达情况,分析其与卵巢上皮性癌临床病理参数之间的关系。结果:正常及良性卵巢组织中PDCD4的阳性表达率明显高于卵巢癌组(P<0.05),卵巢癌的FIGO分期越高,PDCD4的表达越低,卵巢癌的病理分化程度越低,PDCD4的表达也越低,PDCD4的表达与卵巢癌的组织类型、腹水、年龄、是否绝经无关。正常及良性卵巢组织中DNMT1的阳性表达率明显低于卵巢癌组(P<0.05),卵巢癌的病理分化程度越低,DNMT1的表达越高,但其与卵巢癌的FIGO分期、组织类型、腹水、年龄、是否绝经均无关。卵巢癌中DNMT1的与PDCD4的表达呈显著负相关(P<0.05)。结论:PDCD4和DNMT1在卵巢癌中的表达呈负相关,PDCD4的表达下调和DNMT1的表达上调可能在卵巢癌的发生及发展中起重要作用。
Objective: To detect the expression of PDCD4 and DNMT1 in normal ovarian tissue, benign ovarian tumor and epithelial ovarian cancer, and to explore its clinical significance. Methods: The expressions of PDCD4 and DNMT1 in 20 cases of normal ovarian tissue, 25 cases of benign ovarian tumor and 40 cases of ovarian epithelial carcinoma were detected by immunohistochemistry. The relationship between the expression of PDCD4 and DNMT1 was analyzed with the clinicopathological parameters of ovarian epithelial carcinoma. Results: The positive rate of PDCD4 in normal and benign ovarian tissues was significantly higher than that in ovarian cancer (P <0.05). The higher the FIGO stage of ovarian cancer, the lower the expression of PDCD4, the lower the degree of pathological differentiation of ovarian cancer, The lower the expression, PDCD4 expression and ovarian cancer tissue type, ascites, age, whether or not menopause. The positive rate of DNMT1 in normal and benign ovarian tissues was significantly lower than that in ovarian cancer (P <0.05). The lower the degree of pathological differentiation was, the higher the expression of DNMT1 was. However, the positive rate of DNMT1 was not correlated with FIGO staging, Ascites, age, whether menopause or not. There was a significant negative correlation between DNMT1 and PDCD4 expression in ovarian cancer (P <0.05). Conclusion: The expression of PDCD4 and DNMT1 in ovarian cancer is negatively correlated. The down-regulation of PDCD4 and the up-regulation of DNMT1 may play an important role in the development and progression of ovarian cancer.